CL2008002107A1 - Formas polimórficas del ácido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1´h,3h-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-[(metilamino]carbonil]fenoxi}-2-metilpropanoico; proceso de preparacion; composición farmacéutica; dispositivo farmacéutico; y uso en el tratamiento de enfermedades respiratorias. - Google Patents

Formas polimórficas del ácido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1´h,3h-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-[(metilamino]carbonil]fenoxi}-2-metilpropanoico; proceso de preparacion; composición farmacéutica; dispositivo farmacéutico; y uso en el tratamiento de enfermedades respiratorias.

Info

Publication number
CL2008002107A1
CL2008002107A1 CL2008002107A CL2008002107A CL2008002107A1 CL 2008002107 A1 CL2008002107 A1 CL 2008002107A1 CL 2008002107 A CL2008002107 A CL 2008002107A CL 2008002107 A CL2008002107 A CL 2008002107A CL 2008002107 A1 CL2008002107 A1 CL 2008002107A1
Authority
CL
Chile
Prior art keywords
chloro
methylpropanoic
benzofuran
piperidin
spiro
Prior art date
Application number
CL2008002107A
Other languages
English (en)
Inventor
Svetlana Ivanova
Martin Hemerling
Marguerite Mensonides-Harsema
Hakan Schulz
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38957025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002107(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2008002107A1 publication Critical patent/CL2008002107A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C07D303/23—Oxiranylmethyl ethers of compounds having one hydroxy group bound to a six-membered aromatic ring, the oxiranylmethyl radical not being further substituted, i.e.
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Polimorfos derivados del ácido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1ñh,3h-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-[(metilamino]carbonil]fenoxi}-2-metilpropanoico; procedimiento de preparación; composición farmacéutica; dispositivo farmacéutico; y uso en el tratamiento de enfermedades respiratorias.
CL2008002107A 2006-07-19 2008-07-17 Formas polimórficas del ácido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1´h,3h-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-[(metilamino]carbonil]fenoxi}-2-metilpropanoico; proceso de preparacion; composición farmacéutica; dispositivo farmacéutico; y uso en el tratamiento de enfermedades respiratorias. CL2008002107A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83177606P 2006-07-19 2006-07-19
PCT/SE2007/000694 WO2008010765A1 (en) 2006-07-19 2007-07-17 Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity

Publications (1)

Publication Number Publication Date
CL2008002107A1 true CL2008002107A1 (es) 2009-07-17

Family

ID=38957025

Family Applications (2)

Application Number Title Priority Date Filing Date
CL200702099A CL2007002099A1 (es) 2006-07-19 2007-07-18 Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
CL2008002107A CL2008002107A1 (es) 2006-07-19 2008-07-17 Formas polimórficas del ácido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1´h,3h-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-[(metilamino]carbonil]fenoxi}-2-metilpropanoico; proceso de preparacion; composición farmacéutica; dispositivo farmacéutico; y uso en el tratamiento de enfermedades respiratorias.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL200702099A CL2007002099A1 (es) 2006-07-19 2007-07-18 Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.

Country Status (17)

Country Link
US (2) US20080167332A1 (es)
EP (1) EP2069355A4 (es)
JP (1) JP2009543860A (es)
KR (1) KR20090030347A (es)
CN (1) CN101553493B (es)
AR (2) AR061923A1 (es)
AU (1) AU2007275931B2 (es)
BR (1) BRPI0714463A2 (es)
CA (1) CA2657639A1 (es)
CL (2) CL2007002099A1 (es)
IL (1) IL196323A0 (es)
MX (1) MX2009000475A (es)
NO (1) NO20090760L (es)
PE (1) PE20090626A1 (es)
TW (2) TW200821316A (es)
UY (1) UY30493A1 (es)
WO (1) WO2008010765A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
WO2008010765A1 (en) * 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2008103126A1 (en) * 2007-02-23 2008-08-28 Astrazeneca Ab Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
US20110136843A1 (en) * 2007-02-23 2011-06-09 Tomas Eriksson Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
BRPI0821726A2 (pt) 2007-12-20 2015-06-16 Astrazeneca Ab Dispositivo de distribuição e processo de administrar um medicamento em pó via uma corrente de ar
BRPI0822693A2 (pt) 2008-05-13 2015-07-07 Astrazeneca Ab Derivados de quinuclidina como antagonistas do receptor muscarínico m3
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
WO2010007408A2 (en) * 2008-07-14 2010-01-21 Astrazeneca Ab Intermediates 2-(2-chloro-5-hydroxy-4-methylcarbamoylphenoxy)-2-methylpropionic acid tert-butyl ester and glycidyl benzene sulfonates or salts thereof and the process for preparation of said intermediates
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
WO2010042033A1 (en) 2008-10-08 2010-04-15 Astrazeneca Ab Inhalation device and method of dispensing medicament
BRPI0920673A2 (pt) 2008-10-08 2015-12-29 Astrazeneca Ab inalador com indexação vinculada ao movimento de cobertura
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
KR20120035183A (ko) * 2009-06-10 2012-04-13 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
MX2011013368A (es) 2009-07-01 2012-01-20 Astrazeneca Ab Dispensador y metodo para arrastrar polvo en un flujo de aire.
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
BR112012019878A2 (pt) 2010-02-10 2017-10-10 Astrazeneca Uk Ltd processo para fornecimento de um receptáculo cheio para um inalador
CN103118726B (zh) 2010-07-21 2015-07-22 阿斯利康(瑞典)有限公司 吸入器
ES2535701T3 (es) 2010-07-21 2015-05-14 Astrazeneca Ab Inhalador
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
GB201115870D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
GB201115874D0 (en) 2011-09-14 2011-10-26 Astrazeneca Ab Inhaler
EP3730590A1 (de) * 2014-03-10 2020-10-28 Merck Patent GmbH Flüssigkristalline medien mit homöotroper ausrichtung
NL2019273B1 (nl) 2017-07-19 2019-02-25 Synbra Tech B V houder voor vloeistoffen
CN111170753B (zh) * 2020-01-21 2022-05-17 烟台大学 一种具有耐高温性能的含电路屏陶瓷吸波材料及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010201A (en) * 1974-04-12 1977-03-01 The Upjohn Company Organic compounds
US4263317A (en) * 1979-09-06 1981-04-21 Hoechst-Roussel Pharmaceuticals, Inc. Spiro[cyclohexane-1,1'(3'H)-isobenzofuran]s
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
DE3822449A1 (de) * 1988-07-02 1990-01-04 Henkel Kgaa Oxidationshaarfaerbemittel mit neuen kupplern
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
AU2002253342B2 (en) 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
DE10216339A1 (de) 2002-04-13 2003-10-23 Boehringer Ingelheim Pharma Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
US20040092529A1 (en) * 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
HU230612B1 (hu) * 2002-11-27 2017-04-28 Incyte Corporation Kemokin receptorokat módosító hatású 3-aminopirrolidin-származékok
SE0302755D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
US20070021498A1 (en) * 2004-10-14 2007-01-25 Nafizal Hossain Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
JP2007510723A (ja) 2003-11-03 2007-04-26 ノートン　ヘルスケアー　リミテッド ドライパウダー吸入器で使用するためのソフトステロイド組成物
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303280D0 (sv) 2003-12-05 2003-12-05 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) * 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
BRPI0517263A (pt) 2004-10-29 2008-10-07 Astrazeneca Ab novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
WO2008010765A1 (en) * 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
WO2008103126A1 (en) * 2007-02-23 2008-08-28 Astrazeneca Ab Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
US20110136843A1 (en) * 2007-02-23 2011-06-09 Tomas Eriksson Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma

Also Published As

Publication number Publication date
BRPI0714463A2 (pt) 2013-04-02
CN101553493B (zh) 2012-07-04
AR061923A1 (es) 2008-10-01
AU2007275931A1 (en) 2008-01-24
EP2069355A4 (en) 2010-03-24
US20080167332A1 (en) 2008-07-10
IL196323A0 (en) 2009-09-22
CN101553493A (zh) 2009-10-07
CL2007002099A1 (es) 2008-02-22
JP2009543860A (ja) 2009-12-10
MX2009000475A (es) 2009-07-10
NO20090760L (no) 2009-04-14
TW200821316A (en) 2008-05-16
KR20090030347A (ko) 2009-03-24
CA2657639A1 (en) 2008-01-24
UY30493A1 (es) 2008-02-29
US20090176815A1 (en) 2009-07-09
EP2069355A1 (en) 2009-06-17
AR068323A1 (es) 2009-11-11
PE20090626A1 (es) 2009-06-20
WO2008010765A1 (en) 2008-01-24
TW200909433A (en) 2009-03-01
AU2007275931B2 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CL2008002107A1 (es) Formas polimórficas del ácido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1´h,3h-espiro[1-benzofuran-2,4'-piperidin]-1'-il)-2-hidroxipropil]oxi}-4-[(metilamino]carbonil]fenoxi}-2-metilpropanoico; proceso de preparacion; composición farmacéutica; dispositivo farmacéutico; y uso en el tratamiento de enfermedades respiratorias.
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
EP2982696A3 (en) Treatment of acute lymphoblastic leukemia
ZA200803350B (en) Method of acting upon organism by targeted delivery of biologically active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
CA2633594C (en) Means and methods for the treatment of tumorous diseases
IL183982A0 (en) Controlled release formulation for oral administration for treating diabetes containing metformin and methods for the preparation thereof
IL180565A0 (en) An improved stopcock for administering medicaments into the patient's body
PL1730147T3 (pl) Podstawowe związki 1,4,8-triazaspiro[4.5]dekan-2-onu
HK1171736A1 (en) Substituted acids for the treatment of respiratory diseases
WO2005072061A3 (en) Conjugates for cancer therapy and diagnosis
SI1750700T1 (sl) Tekoči pripravek za veterino, postopek za njegovo pripravo in njegova uporaba
AR042705A1 (es) Derivados de pirazol modulador de ppar
WO2007098106A3 (en) Respiratory tract delivery of interferon-tau
HK1099753A1 (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
EP2628746A3 (en) A process for concentration of a polypeptide
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2007095729A8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
TW200637875A (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
WO2005120577A3 (en) Derivatives of chemotherapeutic agents with a formaldehyde releasing moeity
DE602006015358D1 (de) In-vitro-verfahren zum screening zugänglicher biologischer marker in krankhaften geweben
EP1997483A4 (en) NASALE RH EPO FORMULATIONS WITH LOW SIALIC ACID CONCENTRATION FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
WO2008051949A3 (en) Gpr125 as a marker for stem and progenitor cells and methods use thereof
WO2004006831A3 (en) Method and device for inducing biological processes by micro-organs
WO2007071205A3 (en) A taxane derivative containing pharmaceutical composition with improved therapeutic efficacy